Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized, placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine in individuals on antiretroviral therapy
2019-002818-40Phase 2Active
- Sponsor
- Inserm-ANRS
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of vedolizumab and MVA-B in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Inserm-ANRS. Primary endpoint: Primary virological outcome (AUC of HIV RNA). Started Aug 2019; status: active.
02
Drugs
vedolizumabMVA-B
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2019-002818-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002818-40.